BIOLINERX Ltd/S ADR (NASDAQ:BLRX) had its Buy rating reiterated by HC Wainwright with a $4.00 price target

Analyst Ratings For BIOLINERX Ltd/S ADR (NASDAQ:BLRX)

Story continues below

Today, HC Wainwright reiterated its Buy rating on BIOLINERX Ltd/S ADR (NASDAQ:BLRX) with a price target of $4.00.

There are 4 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on BIOLINERX Ltd/S ADR (NASDAQ:BLRX) is Buy with a consensus target price of $3.25 per share, a potential 282.35% upside.

Some recent analyst ratings include

  • 7/30/2018-HC Wainwright Reiterated Rating of Buy.
  • 12/21/2017-Oppenheimer initiated coverage with a Buy rating.
  • 2/13/2017-Rodman & Renshaw initiated coverage with a Buy rating.


    About BIOLINERX Ltd/S ADR (NASDAQ:BLRX)
    BioLineRx Ltd., a clinical stage biopharmaceutical development company focused on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions. The company's other therapeutic candidates comprise BL-1040, a resorbable polymer solution for use in the prevention of ventricular remodeling; BL-9020, which is a monoclonal antibody treatment designed to prevent immune-mediated destruction of insulin-producing beta cells in the pancreas; and BL-1230, a cannabinoid receptor type 2 intended as an anti-inflammatory treatment for dry eye syndrome. The company has collaboration agreement with Novartis Pharma AG to facilitate development and commercialization of Israeli-sourced drug candidates; MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of BL-8040 with Keytruda (pembrolizumab) in pancreatic cancer; and Genentech Inc. to investigate the combination of BL-8040 and Genentech's Atezolizumab in various Phase 1b/2 studies for in various solid tumors and hematologic malignancies. BioLineRx Ltd. was founded in 2003 and is headquartered in Modi'in, Israel.

    Recent Trading Activity for BIOLINERX Ltd/S ADR (NASDAQ:BLRX)
    Shares of BIOLINERX Ltd/S ADR closed the previous trading session at 0,85 −0,0029 0,34 % with 208807 shares trading hands.

    An ad to help with our costs